問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of General Internal Medicine

Division of Hematology & Oncology

Division of Urology

National Health Research Institutes (在職)

Division of Hematology & Oncology

Division of General Internal Medicine

更新時間：2023-09-19

張光裕Chang, Kwang-Yu
  • Principal Investigator
  • Clinical Trial Experience (year) 18 years 1 個月

Recruiting Trial

30Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

張光裕

List

43Cases

2024-10-01 - 2029-09-30

Phase III

Active
A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF PF-06821497 (MEVROMETOSTAT) IN COMBINATION WITH ENZALUTAMIDE COMPARED WITH ENZALUTAMIDE OR DOCETAXEL IN PARTICIPANTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER PREVIOUSLY TREATED WITH ABIRATERONE ACETATE (MEVPRO-1)

  • Condition/Disease

    Metastatic Castrate Resistant Prostate Cancer (mCRPC)

  • Test Drug

    Tablets Soft capsules Infusion solutions

Participate Sites
6Sites

Recruiting6Sites

2021-12-01 - 2024-12-31

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting1Sites

Terminated2Sites

2021-01-01 - 2029-10-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2019-11-01 - 2024-05-13

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
13Sites

Recruiting13Sites

2018-10-30 - 2022-12-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Recruiting10Sites

2020-01-21 - 2024-04-08

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2020-05-12 - 2025-12-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting4Sites

Terminated5Sites

2022-06-16 - 2026-12-31

Phase I

Active

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Recruiting1Sites

2019-12-01 - 2022-12-31

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2020-09-01 - 2025-05-14

Phase I

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

1 2 3 4 5
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB